Cyclin Dependent Kinase 6 – Pipeline Review, H2 2019

“Global Markets Direct’s, ‘Cyclin Dependent Kinase 6 (Cell Division Protein Kinase 6 or Serine/Threonine Protein Kinase PLSTIRE or CDK6 or EC 2.7.11.22)- Pipeline Review, H2 2019’, provides in depth analysis on Cyclin Dependent Kinase 6 (Cell Division Protein Kinase 6 or Serine/Threonine Protein Kinase PLSTIRE or CDK6 or EC 2.7.11.22) targeted pipeline therapeutics. The report provides comprehensive information complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Cyclin Dependent Kinase 6 (Cell Division Protein Kinase 6 or Serine/Threonine Protein Kinase PLSTIRE or CDK6 or EC 2.7.11.22) targeted therapeutics development and features dormant and discontinued projects. The report analyses the pipeline products from therapy areas Oncology, Infectious Disease, Metabolic Disorders and Toxicology under development targeting Cyclin Dependent Kinase 6 (Cell Division Protein Kinase 6 or Serine/Threonine Protein Kinase PLSTIRE or CDK6 or EC 2.7.11.22).

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

*Updated report will be delivered in 48 hours of order confirmation.”

Scope


– The report provides a snapshot of the global therapeutic landscape for Cyclin Dependent Kinase 6 (Cell Division Protein Kinase 6 or Serine/Threonine Protein Kinase PLSTIRE or CDK6 or EC 2.7.11.22)

– The report reviews Cyclin Dependent Kinase 6 (Cell Division Protein Kinase 6 or Serine/Threonine Protein Kinase PLSTIRE or CDK6 or EC 2.7.11.22) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

– The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

– The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

– The report reviews key players involved in Cyclin Dependent Kinase 6 (Cell Division Protein Kinase 6 or Serine/Threonine Protein Kinase PLSTIRE or CDK6 or EC 2.7.11.22) targeted therapeutics and enlists all their major and minor projects

– The report assesses Cyclin Dependent Kinase 6 (Cell Division Protein Kinase 6 or Serine/Threonine Protein Kinase PLSTIRE or CDK6 or EC 2.7.11.22) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

– The report summarizes all the dormant and discontinued pipeline projects

– The report reviews latest news and deals related to Cyclin Dependent Kinase 6 (Cell Division Protein Kinase 6 or Serine/Threonine Protein Kinase PLSTIRE or CDK6 or EC 2.7.11.22) targeted therapeutics”

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

- Identify and understand the targeted therapy areas and indications for Cyclin Dependent Kinase 6 (Cell Division Protein Kinase 6 or Serine/Threonine Protein Kinase PLSTIRE or CDK6 or EC 2.7.11.22)

- Identify the use of drugs for target identification and drug repurposing

- Identify potential new clients or partners in the target demographic

- Develop strategic initiatives by understanding the focus areas of leading companies

- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

- Devise corrective measures for pipeline projects by understanding Cyclin Dependent Kinase 6 (Cell Division Protein Kinase 6 or Serine/Threonine Protein Kinase PLSTIRE or CDK6 or EC 2.7.11.22) development landscape

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Companies mentioned

“Beta Pharma Inc

Betta Pharmaceuticals Co Ltd

CStone Pharmaceuticals Co Ltd

Eli Lilly and Co

ESSA Pharma Inc

Fochon Pharmaceutical Ltd

G1 Therapeutics Inc

Guangzhou BeBetter Medicine Technology Co Ltd

HEC Pharm Co Ltd

Jiangsu Hansoh Pharmaceutical Group Co Ltd

Jiangsu Hengrui Medicine Co Ltd

MEI Pharma Inc

Novartis AG

Onconova Therapeutics Inc

Pfizer Inc

Rizen (Suzhou) Biosciences Co Ltd

Shanghai Haihe Biopharma Co Ltd

Shanghai Haishi Biopharmaceutical Co Ltd

Shanghai Pharmaceutical Group Co Ltd

SignalRx Pharmaceuticals Inc

Sihuan Pharmaceutical Holdings Group Ltd

Sino Biopharmaceutical Ltd

Tetranov International Inc

ViroStatics SRL”

Table of Contents

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Cyclin Dependent Kinase 6 (Cell Division Protein Kinase 6 or Serine/Threonine Protein Kinase PLSTIRE or CDK6 or EC

2.7.11.22) Overview

Cyclin Dependent Kinase 6 (Cell Division Protein Kinase 6 or Serine/Threonine Protein Kinase PLSTIRE or CDK6 or EC

2.7.11.22) Therapeutics Development

Products under Development by Stage of Development

Products under Development by Therapy Area

Products under Development by Indication

Products under Development by Companies

Products under Development by Universities/Institutes

Cyclin Dependent Kinase 6 (Cell Division Protein Kinase 6 or Serine/Threonine Protein Kinase PLSTIRE or CDK6 or EC

2.7.11.22) Therapeutics Assessment

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Cyclin Dependent Kinase 6 (Cell Division Protein Kinase 6 or Serine/Threonine Protein Kinase PLSTIRE or CDK6 or EC

2.7.11.22) Companies Involved in Therapeutics Development

Beta Pharma Inc

Eli Lilly and Co

G1 Therapeutics Inc

Jiangsu Hengrui Medicine Co Ltd

MEI Pharma Inc

MetaMax Ltd

Novartis AG

Onconova Therapeutics Inc

Pfizer Inc

Sihuan Pharmaceutical Holdings Group Ltd

Sino Biopharmaceutical Ltd

Teijin Pharma Ltd

ViroStatics srl

Cyclin Dependent Kinase 6 (Cell Division Protein Kinase 6 or Serine/Threonine Protein Kinase PLSTIRE or CDK6 or EC

2.7.11.22) Drug Profiles

abemaciclib Drug Profile

Product Description

Mechanism Of Action

R&D Progress

BEBT-209 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

BPI-1178 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

G-1T38 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

GZ-381 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

HEC-80797 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

MMD-37K Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ON-123300 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

palbociclib Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ribociclib succinate Drug Profile

Product Description

Mechanism Of Action

R&D Progress

SHR-6390 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule to Inhibit CDK 4 and 6 for Rheumatoid Arthritis Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule to Inhibit CDK1, CDK4 and CDK6 for Colorectal Cancer Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule to Inhibit CDK4 and CDK6 for Colorectal Cancer Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule to Inhibit CDK4 and CDK6 for Oncology Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Inhibit CDK4, CDK6 and CDK9 for EBV Infections Drug Profile

Product Description

Mechanism Of Action

R&D Progress

SRX-3177 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

TQ-05510 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

trilaciclib Drug Profile

Product Description

Mechanism Of Action

R&D Progress

voruciclib Drug Profile

Product Description

Mechanism Of Action

R&D Progress

VS-2370 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

XZP-3287 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Cyclin Dependent Kinase 6 (Cell Division Protein Kinase 6 or Serine/Threonine Protein Kinase PLSTIRE or CDK6 or EC

2.7.11.22) Dormant Products

Cyclin Dependent Kinase 6 (Cell Division Protein Kinase 6 or Serine/Threonine Protein Kinase PLSTIRE or CDK6 or EC

2.7.11.22) Discontinued Products

Cyclin Dependent Kinase 6 (Cell Division Protein Kinase 6 or Serine/Threonine Protein Kinase PLSTIRE or CDK6 or EC

2.7.11.22) Product Development Milestones

Featured News & Press Releases

Jul 26, 2018: Lilly receives CHMP's positive opinion for Verzenios

Jul 18, 2018: FDA approves expanded indication for Novartis drug Kisqali

Jul 09, 2018: TRIO Awarded NATALEE Study, Largest Single Phase III Breast Cancer Clinical Trial in its History

Jun 25, 2018: Pfizer unveils new results from PALOMA-3 trial for breast cancer

Jun 04, 2018: Results From AstraZeneca Study Presented at ASCO

Jun 03, 2018: Third Novartis Phase III trial shows Kisqali combination therapy significantly improves PFS in HR+/HER2- advanced breast cancer

Jun 02, 2018: G1 Therapeutics Presents Phase 1b Data on G1T38 in Combination with Faslodex for Treatment of Breast Cancer at 2018 American Society of Clinical Oncology (ASCO) Annual Meeting

May 16, 2018: Lilly to Present Data on Abemaciclib at ASCO

May 16, 2018: G1 Therapeutics to Present Phase 1b Data on G1T38 in Combination with Faslodex for Treatment of Breast Cancer at 2018 American Society of Clinical Oncology Annual Meeting

May 02, 2018: Health Canada approves KISQALI for the treatment of HR-positive and HER2-negative metastatic breast cancer in postmenopausal women in combination with letrozole as an initial endocrine-based therapy

Apr 19, 2018: Onconova Presents Data on Dual Inhibitor of CDK4/6 + ARK5 at American Association for Cancer Research 2018 Annual Meeting

Apr 17, 2018: Positive results with DiviTum from new Pfizer study presented at the AACR congress

Apr 16, 2018: G1 Therapeutics Announces Initiation of Phase 1b/2 Clinical Trial of G1T38 in Combination with Tagrisso for EGFR-Mutant Non-Small Cell Lung Cancer

Apr 09, 2018: G1 Therapeutics to Present Preclinical Data on CDK4/6 Inhibitor Trilaciclib at the 2018 American Association for Cancer Research (AACR) Annual Meeting

Apr 09, 2018: G1 Therapeutics to Present Preclinical Data on G1T38 at the 2018 American Association for Cancer Research (AACR) Annual Meeting

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

“List of Tables

Number of Products under Development by Stage of Development, H2 2019

Number of Products under Development by Therapy Areas, H2 2019

Number of Products under Development by Indications, H2 2019

Number of Products under Development by Indications, H2 2019 (Contd..1), H2 2019

Number of Products under Development by Indications, H2 2019 (Contd..2), H2 2019

Number of Products under Development by Indications, H2 2019 (Contd..3), H2 2019

Number of Products under Development by Indications, H2 2019 (Contd..4), H2 2019

Number of Products under Development by Companies, H2 2019

Number of Products under Development by Companies, H2 2019 (Contd..1)

Products under Development by Companies, H2 2019

Products under Development by Companies, H2 2019 (Contd..1), H2 2019

Products under Development by Companies, H2 2019 (Contd..2), H2 2019

Products under Development by Companies, H2 2019 (Contd..3), H2 2019

Products under Development by Companies, H2 2019 (Contd..4), H2 2019

Products under Development by Companies, H2 2019 (Contd..5), H2 2019

Products under Development by Companies, H2 2019 (Contd..6), H2 2019

Products under Development by Companies, H2 2019 (Contd..7), H2 2019

Products under Development by Companies, H2 2019 (Contd..8), H2 2019

Number of Products under Investigation by Universities/Institutes, H2 2019

Products under Investigation by Universities/Institutes, H2 2019

Number of Products by Stage and Mechanism of Actions, H2 2019

Number of Products by Stage and Route of Administration, H2 2019

Number of Products by Stage and Molecule Type, H2 2019

Pipeline by Beta Pharma Inc, H2 2019

Pipeline by Betta Pharmaceuticals Co Ltd, H2 2019

Pipeline by CStone Pharmaceuticals Co Ltd, H2 2019

Pipeline by Eli Lilly and Co, H2 2019

Pipeline by ESSA Pharma Inc, H2 2019

Pipeline by Fochon Pharmaceutical Ltd, H2 2019

Pipeline by G1 Therapeutics Inc, H2 2019

Pipeline by Guangzhou BeBetter Medicine Technology Co Ltd, H2 2019

Pipeline by HEC Pharm Co Ltd, H2 2019

Pipeline by Jiangsu Hansoh Pharmaceutical Group Co Ltd, H2 2019

Pipeline by Jiangsu Hengrui Medicine Co Ltd, H2 2019

Pipeline by MEI Pharma Inc, H2 2019

Pipeline by Novartis AG, H2 2019

Pipeline by Onconova Therapeutics Inc, H2 2019

Pipeline by Pfizer Inc, H2 2019

Pipeline by Rizen (Suzhou) Biosciences Co Ltd, H2 2019

Pipeline by Shanghai Haihe Biopharma Co Ltd, H2 2019

Pipeline by Shanghai Haishi Biopharmaceutical Co Ltd, H2 2019

Pipeline by Shanghai Pharmaceutical Group Co Ltd, H2 2019

Pipeline by SignalRx Pharmaceuticals Inc, H2 2019

Pipeline by Sihuan Pharmaceutical Holdings Group Ltd, H2 2019

Pipeline by Sino Biopharmaceutical Ltd, H2 2019

Pipeline by Tetranov International Inc, H2 2019

Pipeline by ViroStatics SRL, H2 2019

Dormant Products, H2 2019

Dormant Products, H2 2019 (Contd..1), H2 2019

Dormant Products, H2 2019 (Contd..2), H2 2019

Discontinued Products, H2 2019”

List of Figures

“List of Figures

Number of Products under Development by Stage of Development, H2 2019

Number of Products under Development by Therapy Areas, H2 2019

Number of Products under Development by Top 10 Indications, H2 2019

Number of Products by Stage and Mechanism of Actions, H2 2019

Number of Products by Routes of Administration, H2 2019

Number of Products by Stage and Routes of Administration, H2 2019

Number of Products by Stage and Molecule Type, H2 2019”

    Pricing

Discounts available for multiple report purchases.

reportstore@globalmarketsdirect.com
+44 (0) 161 359 5414

Saved reports